[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 39 of about 39
1. Paton F, Paulden M, Saramago P, Manca A, Misso K, Palmer S, Eastwood A: Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix. Health Technol Assess; 2010 May;14 Suppl 1:55-62
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix.
  • This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of topotecan in combination with cisplatin for the treatment of recurrent and stage IVB carcinoma of the cervix, in accordance with the licensed indication, based upon the evidence submission from the manufacturer to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process.
  • The outcomes measured were overall survival, progression-free survival, response rates, adverse effects of treatment, health-related quality of life (HRQoL) and quality-adjusted life-years (QALYs) gained.
  • The clinical evidence came from three clinical trials comparing topotecan plus cisplatin with cisplatin monotherapy (GOG-0179), topotecan plus cisplatin with paclitaxel plus cisplatin (GOG-0169), and four cisplatin-based combination therapies: topotecan plus cisplatin, paclitaxel plus cisplatin, gemcitabine plus cisplatin, and vinorelbine plus cisplatin (GOG-0204).
  • In the base-case direct comparison, the incremental cost-effectiveness ratio (ICER) of topotecan plus cisplatin versus cisplatin monotherapy was 17,974 pounds per QALY in the main licensed population, 10,928 pounds per QALY in the cisplatin-naive population (including stage IVB patients) and 32,463 pounds per QALY in sustained cisplatin-free interval patients.
  • In response to the point for clarification raised by the ERG, the manufacturer submitted a revised indirect comparison incorporating HRQoL and a longer time horizon.
  • At present there is a paucity of evidence available on the clinical effects of topotecan plus cisplatin and the effects of palliative treatment in general for women with advanced and recurrent carcinoma of the cervix.
  • The guidance issued by NICE on 28 October 2009 as a result of the STA states that topotecan in combination with cisplatin is recommended as a treatment option for women with recurrent or stage IVB cervical cancer, only if they have not previously received cisplatin.
  • Women who have previously received cisplatin and are currently being treated with topotecan in combination with cisplatin for the treatment of cervical cancer should have the option to continue therapy until they and their clinicians consider it appropriate to stop.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Cisplatin / therapeutic use. Topotecan / therapeutic use. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Cost-Benefit Analysis. Cross-Linking Reagents / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Disease Progression. Drug Therapy, Combination / economics. Female. Great Britain. Humans. Neoplasm Recurrence, Local. Neoplasm Staging. Quality of Life. Quality-Adjusted Life Years. Radiation-Sensitizing Agents / therapeutic use. Treatment Outcome. Vinblastine / analogs & derivatives. Vinblastine / therapeutic use

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20507804.001).
  • [ISSN] 2046-4924
  • [Journal-full-title] Health technology assessment (Winchester, England)
  • [ISO-abbreviation] Health Technol Assess
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Cross-Linking Reagents; 0 / Radiation-Sensitizing Agents; 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; 7M7YKX2N15 / Topotecan; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  • [Number-of-references] 50
  •  go-up   go-down


2. Lin S, Lu JJ, Han L, Chen Q, Pan J: Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: experience of 370 consecutive cases. BMC Cancer; 2010;10:39
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: experience of 370 consecutive cases.
  • INTRODUCTION: To investigate the outcome of locoregionally advanced nasopharyngeal carcinoma (NPC) treated with intensity-modulated radiation therapy (IMRT) after induction chemotherapy, with or without concomitant chemotherapy.
  • Presenting stages were stage IIB in 62, stage III in 197, and stage IVA/B in 111 patients.
  • All patients except for 36 patients with cervical lymphadenopathy of 4 cm or less in diameter received 2 cycles of cisplatin-based neoadjuvant chemotherapy.
  • Forty-eight patients received cisplatin-based concurrent chemotherapy as well.
  • RESULTS: With a median follow-up time of 31 months (range 5 to 61 months), the 3-year local control, regional control, metastasis-free survival (MFS), disease-free survival (DFS) and overall survival (OS) rates were 95%, 97%, 86%, 81% and 89%, respectively.
  • T-classification and concurrent chemotherapy were not significant prognostic factors for local/regional control, MFS, DFS, or OS.
  • Subgroup analysis revealed that concurrent chemotherapy provided no significant benefit to IMRT in locoregionally advanced NPC, but was responsible for higher rates of grade 3 or 4 acute toxicities (50% vs. 29.8%, P < 0.005).
  • However, two patients treated with IMRT and neoadjuvant but without concurrent and adjuvant chemotherapy died of treatment related complications.
  • CONCLUSION: IMRT following neoadjuvant chemotherapy produced a superb outcome in terms of local control, regional control, MFS, DFS, and OS rates in patients with stage IIB to IVB NPC.
  • Effective treatment strategy is urgently needed for distant control in patients diagnosed with locoregionally advanced NPC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cisplatin / adverse effects. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Radiotherapy / adverse effects. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):985-96 [9169804.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Aug;11(8):1455-9 [3926733.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1440-50 [15590175.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6730-8 [16170180.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):47-56 [16377415.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1071-8 [19362784.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1481-6 [19386431.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6 [7713792.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):861-6 [10863053.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):329-37 [10974445.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1277-9 [11121623.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1323-30 [11121629.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1350-7 [11230478.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2038-44 [11956263.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):12-22 [12007936.001]
  • [Cites] Radiother Oncol. 2003 Dec;69(3):227-36 [14644481.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1584-93 [15378492.001]
  • [Cites] Cancer. 1980 Jun 1;45(11):2725-9 [7379006.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1310-7 [9552031.001]
  • (PMID = 20146823.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2836300
  •  go-up   go-down


3. Cella D, Huang HQ, Monk BJ, Wenzel L, Benda J, McMeekin DS, Cohn D, Ramondetta L, Boardman CH: Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol; 2010 Dec;119(3):531-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study.
  • PURPOSE: To assess the differences in health-related quality of life (HRQL) of 4 cisplatin containing doublet chemotherapy combinations in women with advanced/recurrent cervical carcinoma.
  • HRQL was assessed with the Functional Assessment of Cancer Therapy-Cervix (FACT-Cx) the FACT/Gynecologic Oncology Group (FACT/GOG) four-item neurotoxicity scale, and the 0-10 "worst pain" item from the Brief Pain Inventory, at baseline (pre-treatment), prior to beginning cycle 2, prior to beginning cycle 5, and at 9 months after enrollment.
  • Patients receiving PC tended to report worse neuropathy during treatment than patients who received other doublets (especially GC and TC), but the differences were not statistically significant.
  • CONCLUSION: None of the 3 experimental doublets was different from PC in terms of HRQL during treatment.
  • Except where patients may wish to reduce their risk of worsening pre-treatment neuropathy, PC remains the standard of care for this disease.

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20837359.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / U10 CA027469; United States / NCI NIH HHS / CA / U10 CA037517; United States / NCI NIH HHS / CA / CA 37517; United States / NCI NIH HHS / CA / P30 CA062203
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; 7M7YKX2N15 / Topotecan; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  • [Other-IDs] NLM/ NIHMS707946; NLM/ PMC4687012
  •  go-up   go-down


Advertisement
4. Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, Benda J, Cella D: Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol; 2009 Oct 1;27(28):4649-55
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.
  • PURPOSE: Assess toxicity and efficacy of cisplatin (Cis) doublet combinations in advanced and recurrent cervical carcinoma.
  • Differences in chemotherapy scheduling, pre-existing morbidity, and toxicity are important in individualizing therapy.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3113-9 [15284262.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3340-4 [15310778.001]
  • [Cites] Stat Med. 1994 Jul 15-30;13(13-14):1453-8 [7973224.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4617-25 [15911864.001]
  • [Cites] J Clin Oncol. 2009 Mar 1;27(7):1069-74 [19139430.001]
  • [Cites] Curr Oncol Rep. 2005 Nov;7(6):419-34 [16221379.001]
  • [Cites] Gynecol Oncol. 2006 Feb;100(2):385-8 [16271750.001]
  • [Cites] Gynecol Oncol. 2007 May;105(2):427-33 [17275889.001]
  • [Cites] J Clin Oncol. 2007 Jul 10;25(20):2952-65 [17617527.001]
  • [Cites] Am J Obstet Gynecol. 2007 Oct;197(4):337-9 [17904955.001]
  • [Cites] Am J Obstet Gynecol. 2008 Nov;199(5):539.e1-6 [18565487.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4626-33 [15911865.001]
  • (PMID = 19720909.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K-23 CA 87558; United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / U10 CA027469; United States / NCI NIH HHS / CA / U10 CA037517; United States / NCI NIH HHS / CA / CA 37517; United States / NCI NIH HHS / CA / K23 CA087558
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; 7M7YKX2N15 / Topotecan; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  • [Other-IDs] NLM/ PMC2754911
  •  go-up   go-down


5. Brave M, Dagher R, Farrell A, Abraham S, Ramchandani R, Gobburu J, Booth B, Jiang X, Sridhara R, Justice R, Pazdur R: Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer. Oncology (Williston Park); 2006 Oct;20(11):1401-4, 1410; discussion 1410-11, 1415-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer.
  • PURPOSE: Topotecan, a camptothecin analog previously approved for the treatment of ovarian cancer and small-cell lung cancer, was granted regular approval by the US Food and Drug Administration (FDA) on June 14, 2006, for use in combination with cisplatin to treat women with stage IVB, recurrent, or persistent carcinoma of the cervix not amenable to curative treatment with surgery and/or radiation therapy.
  • RESULTS: There was a clinically relevant and statistically significant improvement in overall survival in the TC treatment arm.
  • The unadjusted hazard ratio for overall survival between treatment arms was 0.76 (95% CI: 0.59-0.98, P = .033) favoring the combination arm.
  • CONCLUSIONS: This report describes the FDA's review supporting this first approval of a chemotherapeutic drug for advanced cervical cancer based on demonstration of a survival benefit.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Cisplatin / administration & dosage. Female. Humans. Neoplasm Staging. Survival Rate. Topotecan / administration & dosage


6. Hsiao SM, Chen CA, Hsu C, Lin HH, Hsieh CY, Wei LH: Weekly cisplatin, infusional high-dose 5-fluorouracil and leucovorin for advanced, recurrent and metastatic cervical carcinoma. Anticancer Res; 2008 May-Jun;28(3B):1887-91
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly cisplatin, infusional high-dose 5-fluorouracil and leucovorin for advanced, recurrent and metastatic cervical carcinoma.
  • BACKGROUND: To evaluate the effectiveness and toxicity of infusional cisplatin and weekly 24-hour infusion of high-dose fluorouracil plus leucovorin (P-HDFL) for the treatment of patients with stage IVB, recurrent and metastatic carcinoma of the cervix.
  • PATIENTS AND METHODS: A phase II study of P-HDFL in stage IVB, recurrent and metastatic carcinoma of cervix was initiated in January 2001.
  • CONCLUSION: P-HDFL appears to be a moderately effective regimen with low toxicity for treating patients with advanced, recurrent and metastatic cervical cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Uterine Cervical Neoplasms / drug therapy


7. Chan JK, Loizzi V, Burger RA, Rutgers J, Monk BJ: Prognostic factors in neuroendocrine small cell cervical carcinoma: a multivariate analysis. Cancer; 2003 Feb 1;97(3):568-74
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in neuroendocrine small cell cervical carcinoma: a multivariate analysis.
  • BACKGROUND: The purpose of this study was to evaluate the clinical and pathologic factors associated with survival in patients with neuroendocrine (NE) cervical carcinoma.
  • METHODS: All patients with NE cervical carcinoma diagnosed between 1979-2001 were identified from tumor registry databases at two hospitals.
  • The impact of clinical and pathologic risk factors on the survival of patients with small cell NE carcinoma of the cervix was evaluated using Kaplan-Meier life table analyses and log-rank tests.
  • RESULTS: Thirty-four patients (median age, 42 years) were diagnosed with neuroendocrine cervical carcinoma, which included 21 with International Federation of Gynecology and Obstetrics (FIGO) Stage I disease, 6 with FIGO Stage II disease, 5 with FIGO Stage III disease, and 2 with FIGO Stage IV disease.
  • Fourteen women received adjuvant therapy with pelvic radiation and/or cisplatin-based chemotherapy.
  • Ten women received primary radiotherapy with (n = 5) or without (n = 4) chemotherapy and the remaining patient refused therapy.
  • Women with early-stage (Stage I-IIA) disease had median survival rates of 31 months compared with 10 months in the advanced-stage (Stage IIB-IVB) group (P = 0.002).
  • In univariate analysis, advanced stage (P = 0.002), tumor size >2 cm (P = 0.02), margin involvement (P = 0.016), pure versus a mixed histologic pattern (P = 0.04), margin status (P = 0.016), and smoking (P = 0.04) were considered poor prognostic factors.
  • In multivariate analysis, smoking for early-stage patients and stage of disease in the overall population remained as independent prognostic factors of survival.
  • CONCLUSIONS: Smoking and advanced stage are reported to be poor prognostic factors for survival in patients with NE small cell carcinoma of the cervix.
  • The role of primary or postoperative radiation with or without chemotherapy is unclear and yields uniformly poor results, particularly in patients with advanced lesions.
  • [MeSH-major] Carcinoma, Small Cell / mortality. Uterine Cervical Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11086
  • (PMID = 12548598.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Zighelboim I, Taylor NP, Powell MA, Gibb RK, Rader JS, Mutch DG, Grigsby PW: Outcomes in 24 selected patients with stage IVB cervical cancer and excellent performance status treated with radiotherapy and chemotherapy. Radiat Med; 2006 Nov;24(9):625-30
Hazardous Substances Data Bank. PLATINUM COMPOUNDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes in 24 selected patients with stage IVB cervical cancer and excellent performance status treated with radiotherapy and chemotherapy.
  • PURPOSE: We sought to review outcomes in patients with stage IVB carcinoma of the cervix treated with irradiation in combination with chemotherapy.
  • Most of these patients underwent concurrent irradiation with platinum-based chemotherapy.
  • Some patients received subsequent systemic chemotherapy.
  • The mean dose to point A was variable (73.9 +/- 19.2 Gy).
  • Twenty patients (83%) received radio-sensitizing platinum-based chemotherapy, and the remaining had radiotherapy alone.
  • Seven patients (29%) had further combination chemotherapy.
  • Therapy was well tolerated.
  • CONCLUSION: Patients with stage IVB cervical cancer have mostly been treated with palliative intent.
  • With the advent of concurrent chemoradiation, we have treated many of these cases with aggressive combination therapy.
  • In this series, the use of radiotherapy and multiagent chemotherapy in patients with stage IVB cervical carcinoma and good performance status was well tolerated and resulted in higher survival rates than previously reported.
  • [MeSH-major] Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Brachytherapy. Combined Modality Therapy. Female. Humans. Middle Aged. Platinum Compounds / therapeutic use. Radiotherapy Dosage. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):635-8 [14766258.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):805-9 [15721429.001]
  • [Cites] Cancer. 1987 Oct 15;60(8 Suppl):2104-16 [3308070.001]
  • [Cites] Gynecol Oncol. 1999 Dec;75(3):334-7 [10600285.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4626-33 [15911865.001]
  • [Cites] Eur J Gynaecol Oncol. 2002;23(2):115-9 [12013105.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Gynecol Oncol. 1989 Nov;35(2):150-5 [2807004.001]
  • [Cites] Semin Oncol. 1992 Apr;19(2 Suppl 5):9-17; discussion 17-8 [1384148.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1275-8 [11230468.001]
  • [Cites] Cancer. 1993 Apr 1;71(7):2245-9 [8453545.001]
  • [Cites] Lancet. 2001 Sep 8;358(9284):781-6 [11564482.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):402-7 [12798702.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3113-9 [15284262.001]
  • [Cites] Am J Clin Oncol. 2002 Dec;25(6):547-51 [12477995.001]
  • [Cites] Ann Oncol. 1999 Oct;10(10):1171-4 [10586332.001]
  • [Cites] Gynecol Oncol. 2002 Jun;85(3):476-82 [12051877.001]
  • [Cites] Br J Obstet Gynaecol. 1989 Aug;96(8):889-92 [2775686.001]
  • [Cites] J Natl Cancer Inst Monogr. 1996;(21):127-30 [9023842.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2676-80 [10561341.001]
  • [Cites] Am J Clin Oncol. 1988 Apr;11(2):149-51 [2451883.001]
  • (PMID = 17111271.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Platinum Compounds
  •  go-up   go-down


9. Kamnerdsupaphon P, Chitapanarux I, Tharavichitkul E, Sukthomya V, Lorvidhaya V: The study of cisplatin and vinorelbine in metastatic uterine cervical cancer. J Med Assoc Thai; 2009 Jun;92(6):836-40
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The study of cisplatin and vinorelbine in metastatic uterine cervical cancer.
  • OBJECTIVE: To determine the therapeutic efficacy of cisplatin in combination with vinorelbine in the treatment of patients with metastatic cervical cancer.
  • There were 6 patients who were diagnosed as stage IVB cervical cancer without previous treatment.
  • CONCLUSION: Cisplatin-vinorelbine is an active and well-tolerated regimen in metastatic cervical carcinoma.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Antineoplastic Agents, Phytogenic / therapeutic use. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cisplatin / therapeutic use. Disease Progression. Female. Humans. Middle Aged. Neoplasm Metastasis. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vinblastine / analogs & derivatives. Vinblastine / therapeutic use


10. Lorvidhaya V, Kamnerdsupaphon P, Chitapanarux I, Sukthomya V, Tonusin A: Cisplatin and gemcitabine in patients with metastatic cervical cancer. Gan To Kagaku Ryoho; 2004 Jul;31(7):1057-62
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin and gemcitabine in patients with metastatic cervical cancer.
  • PURPOSE: To determine the therapeutic efficacy of cisplatin plus gemcitabine in the treatment of patients with metastatic cervical cancer.
  • There were 14 patients with stage IVB cervical cancer who were previously untreated.
  • Eleven patients were not assessable because of patient refusal for further treatment and loss of follow up.
  • There were 3 (5.8%) patients who developed grade 4 neutropenia and fever.
  • There were no treatment related deaths.
  • The median time to progression was 8.3 months and the median survival was 9.6 months.
  • CONCLUSION: In this study of patients with metastatic cervical cancer, the combination of cisplatin and gemcitabine treatment induced a high response rate.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Deoxycytidine / analogs & derivatives. Lymph Nodes / pathology. Uterine Cervical Neoplasms / drug therapy


11. Dueñas-González A, Cetina L, Coronel J, Martínez-Baños D: Pharmacotherapy options for locally advanced and advanced cervical cancer. Drugs; 2010 Mar 05;70(4):403-32
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacotherapy options for locally advanced and advanced cervical cancer.
  • Cervical cancer continues to be a significant health burden worldwide.
  • Globally, the majority of cancers are locally advanced at diagnosis; hence, radiation remains the most frequently used therapeutic modality.
  • Currently, the value of adding cisplatin or cisplatin-based chemotherapy to radiation for the treatment of locally advanced cervical cancer is strongly supported by randomized studies and meta-analyses.
  • Nevertheless, despite these significant achievements, therapeutic results are far from optimal; thus, novel therapies need to be investigated.
  • A recent, randomized, phase III trial has shown for the first time that combination chemotherapy with cisplatin and gemcitabine concurrently with radiation improves parameters of survival over cisplatin alone and establishes a new standard for the management of locally advanced cervical cancer.
  • On the other hand, advanced disease, presenting either as an International Federation of Gynecology and Obstetrics (FIGO) stage IVB or as persistent or recurrent to primary therapy without local curative options, remains a devastating group of diseases with no options other than palliative chemotherapy.
  • The role of targeted therapies both in locally advanced and advanced disease is promising, but still at an investigational stage.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Female. Humans

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1606-13 [10764420.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):991-8 [10571207.001]
  • [Cites] Gynecol Oncol. 2006 Feb;100(2):385-8 [16271750.001]
  • [Cites] Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1367-71 [18217969.001]
  • [Cites] Gynecol Oncol. 2009 Apr;113(1):16-20 [19232434.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):386-90 [9887236.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4137-45 [15961761.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2908-9; author reply 2809-10 [12065571.001]
  • [Cites] J Natl Cancer Inst Monogr. 1996;(21):93-9 [9023836.001]
  • [Cites] Eur J Gynaecol Oncol. 2003;24(6):513-6 [14658592.001]
  • [Cites] Am J Obstet Gynecol. 2007 Nov;197(5):503.e1-6 [17980189.001]
  • [Cites] Strahlenther Onkol. 2000 Sep;176(9):422-8 [11050916.001]
  • [Cites] Eur J Gynaecol Oncol. 1998;19(1):35-8 [9476056.001]
  • [Cites] Clin Pharmacokinet. 1978 Jul-Aug;3(4):330-6 [678346.001]
  • [Cites] Int Semin Surg Oncol. 2006 Feb 03;3:3 [16457727.001]
  • [Cites] Semin Oncol. 1997 Apr;24(2 Suppl 7):S7-24-S7-28 [9194476.001]
  • [Cites] Cochrane Database Syst Rev. 2005 Jul 20;(3):CD002225 [16034873.001]
  • [Cites] Radiother Oncol. 1995 Dec;37(3):181-9 [8746586.001]
  • [Cites] Nephron. 1999;83(2):122-5 [10516490.001]
  • [Cites] J Clin Oncol. 2009 Mar 1;27(7):1069-74 [19139430.001]
  • [Cites] Gynecol Oncol. 2007 Nov;107(2):274-9 [17688925.001]
  • [Cites] Int J Cancer. 2001 Mar 15;91(6):778-82 [11275979.001]
  • [Cites] Gynecol Oncol. 1997 May;65(2):336-42 [9159348.001]
  • [Cites] Oncology (Williston Park). 1999 Oct;13(10 Suppl 5):39-46 [10550825.001]
  • [Cites] Anticancer Drugs. 2004 Sep;15(8):761-6 [15494637.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1226-32 [12654431.001]
  • [Cites] Gynecol Oncol. 1997 Nov;67(2):131-6 [9367695.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1284-7 [12873672.001]
  • [Cites] Drugs. 1993 Sep;46(3):360-377 [7693428.001]
  • [Cites] Gynecol Oncol. 2008 Jan;108(1):42-6 [17980406.001]
  • [Cites] Am J Obstet Gynecol. 2007 Aug;197(2):205.e1-5; discussion 205.e5-7 [17689652.001]
  • [Cites] Surg Gynecol Obstet. 1956 Sep;103(3):337-41 [13360640.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2009 Aug;21(6):488-93 [19386478.001]
  • [Cites] Gynecol Oncol. 2000 Nov;79(2):272-80 [11063656.001]
  • [Cites] J Clin Oncol. 1985 Aug;3(8):1079-85 [3894589.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):790-5 [15894361.001]
  • [Cites] Gynecol Oncol. 2005 Jul;98(1):54-8 [15904950.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):1038-42 [16889823.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 May;49(5):385-90 [11976832.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4626-33 [15911865.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8289-95 [16230678.001]
  • [Cites] Eur J Gynaecol Oncol. 2002;23(2):115-9 [12013105.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):153-6 [11668491.001]
  • [Cites] Gynecol Oncol. 2005 Jan;96(1):194-7 [15589600.001]
  • [Cites] Tumori. 1986 Aug 31;72(4):339-44 [3532468.001]
  • [Cites] Int J Gynecol Cancer. 2009 Jul;19(5):929-33 [19574787.001]
  • [Cites] Cancer Treat Rev. 2004 Aug;30(5):405-14 [15245773.001]
  • [Cites] Int J Gynecol Cancer. 2008 Sep-Oct;18(5):1037-41 [18021215.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Oct;15(4):893-9 [3141318.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):1092-8 [11958906.001]
  • [Cites] Acta Oncol. 1991;30(3):325-7 [2036241.001]
  • [Cites] Ann Oncol. 1998 Jan;9(1):13-21 [9541678.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):483-7 [15297192.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1361-5 [12873681.001]
  • [Cites] Gynecol Oncol. 1998 Nov;71(2):308-12 [9826477.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1339-48 [10334517.001]
  • [Cites] Eur J Gynaecol Oncol. 2008;29(3):222-4 [18592783.001]
  • [Cites] Gynecol Oncol. 2007 May;105(2):299-303 [17303230.001]
  • [Cites] Eur J Gynaecol Oncol. 2008;29(6):608-12 [19115688.001]
  • [Cites] Gynecol Oncol. 2001 Apr;81(1):88-91 [11277656.001]
  • [Cites] Int J Gynecol Cancer. 2003 Mar-Apr;13(2):164-9 [12657118.001]
  • [Cites] BMC Womens Health. 2006 Feb 07;6:3 [16464243.001]
  • [Cites] Cancer Treat Rev. 1985 Sep;12 Suppl A:111-24 [3910216.001]
  • [Cites] Ann Surg Oncol. 2004 Apr;11(4):445-52 [15070607.001]
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):128-31 [11161849.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1274-81 [9849491.001]
  • [Cites] Gynecol Oncol. 1998 May;69(2):137-45 [9600821.001]
  • [Cites] Eur J Gynaecol Oncol. 2007;28(5):352-5 [17966212.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2055-60 [10561258.001]
  • [Cites] Int J Cancer. 2000 Aug 20;90(4):206-23 [10993961.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):577-86 [10100709.001]
  • [Cites] Oncologist. 2009 Aug;14(8):828-34 [19661184.001]
  • [Cites] Cancer Cell Int. 2006 Oct 02;6:22 [17014709.001]
  • [Cites] Gynecol Oncol. 2009 Jan;112(1):85-9 [18977518.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1832-7 [11919241.001]
  • [Cites] Contrib Nephrol. 1980;23:34-46 [7002453.001]
  • [Cites] Gynecol Oncol. 2005 Jul;98(1):3-10 [15936061.001]
  • [Cites] Cancer. 1993 Oct 15;72(8):2389-93 [8402454.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):685-90 [9485021.001]
  • [Cites] Am J Clin Oncol. 2003 Feb;26(1):22-5 [12576919.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4649-55 [19720909.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):70-5 [16288803.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1154-61 [10202166.001]
  • [Cites] Ann Oncol. 2003 Aug;14(8):1285-90 [12881394.001]
  • [Cites] Gynecol Oncol. 2002 Apr;85(1):89-94 [11925125.001]
  • [Cites] Ann Oncol. 2003 Aug;14(8):1278-84 [12881393.001]
  • [Cites] Am J Clin Oncol. 1997 Dec;20(6):613-20 [9391552.001]
  • [Cites] Aust N Z J Obstet Gynaecol. 2008 Oct;48(5):517-8 [19032670.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1137-43 [10202164.001]
  • [Cites] Semin Hematol. 1994 Oct;31(4 Suppl 5):31-7 [7831583.001]
  • [Cites] Oncol Rep. 2008 Jun;19(6):1551-6 [18497964.001]
  • [Cites] Gynecol Oncol. 1995 Mar;56(3):382-6 [7705672.001]
  • [Cites] Acta Oncol. 2005;44(7):687-93 [16227158.001]
  • [Cites] Eur J Cancer. 2003 Nov;39(17):2470-86 [14602133.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):641-61 [11895891.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1144-53 [10202165.001]
  • [Cites] Lancet. 2001 Sep 8;358(9284):781-6 [11564482.001]
  • [Cites] J Med Assoc Thai. 2003 May;86(5):430-5 [12859099.001]
  • [Cites] Anticancer Drugs. 1994 Dec;5(6):645-9 [7888702.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 Dec;48(6):488-92 [11800030.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2948-53 [10537364.001]
  • [Cites] J Clin Oncol. 2008 Dec 10;26(35):5802-12 [19001332.001]
  • [Cites] Ann Oncol. 1998 Sep;9(9):977-80 [9818071.001]
  • [Cites] Cancer Res. 1990 Dec 1;50(23):7483-9 [1701346.001]
  • [Cites] Gynecol Oncol. 2002 Apr;85(1):185-7 [11925142.001]
  • [Cites] Gynecol Oncol. 2001 Aug;82(2):333-7 [11531289.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):814-21 [15465198.001]
  • [Cites] Gynecol Oncol. 2005 Jan;96(1):168-72 [15589596.001]
  • [Cites] Gynecol Oncol. 2008 Dec;111(3):438-43 [18835493.001]
  • [Cites] Gynecol Oncol. 1996 Feb;60(2):251-4 [8631547.001]
  • [Cites] Cancer Treat Rev. 2004 Aug;30(5):437-49 [15245776.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):165-71 [8996138.001]
  • [Cites] Obstet Gynecol. 1999 May;93(5 Pt 1):761-5 [10912982.001]
  • [Cites] Ann Oncol. 2000 Apr;11(4):455-9 [10847466.001]
  • [Cites] Gynecol Oncol. 2006 May;101(2):367-70 [16542714.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3113-9 [15284262.001]
  • [Cites] Gynecol Oncol. 1997 Sep;66(3):351-61 [9312522.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3194-200 [12860964.001]
  • [Cites] Ann Oncol. 2009 Aug;20(8):1362-8 [19457937.001]
  • [Cites] Clin Cancer Res. 2008 Oct 1;14(19):6324-9 [18829516.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3340-4 [15310778.001]
  • [Cites] Lung Cancer. 2001 Dec;34(3):451-60 [11714543.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):817-23 [15708261.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):979-87 [9276362.001]
  • [Cites] Lancet. 1997 Aug 23;350(9077):535-40 [9284774.001]
  • [Cites] N Engl J Med. 1994 Aug 25;331(8):502-7 [8041415.001]
  • [Cites] N Engl J Med. 1992 Feb 20;326(8):524-30 [1310160.001]
  • [Cites] Strahlenther Onkol. 1997 May;173(5):281-6 [9176559.001]
  • [Cites] Gynecol Oncol. 1995 May;57(2):165-9 [7729728.001]
  • [Cites] Int J Gynecol Cancer. 2009 Dec;19(9):1632-7 [19955950.001]
  • [Cites] Cancer. 1989 Apr 1;63(7):1279-82 [2920356.001]
  • [Cites] Cancer Invest. 2004;22(3):368-73 [15493357.001]
  • [Cites] Ann Oncol. 2001 Apr;12(4):541-7 [11398890.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1190-7 [15026800.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2676-80 [10561341.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1212-9 [12181244.001]
  • [Cites] Semin Oncol. 1996 Apr;23(2 Suppl 5):41-7 [8610236.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Oct;15(4):901-6 [3141319.001]
  • [Cites] Gynecol Oncol. 1989 Feb;32(2):198-202 [2910782.001]
  • [Cites] Ann Oncol. 2009 Apr;20(4):660-5 [19181826.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):756-60 [10071263.001]
  • [Cites] J Clin Oncol. 1999 Oct;17 (10 ):3136-42 [10506610.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Sep;10(9):1785-90 [6434500.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Int J Gynecol Cancer. 2009 May;19(4):777-81 [19509587.001]
  • [Cites] Oncologist. 2005 Jan;10(1):34-51 [15632251.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):95-8 [10487618.001]
  • [Cites] J Natl Cancer Inst. 1992 Feb 19;84(4):241-5 [1734085.001]
  • [Cites] Am J Obstet Gynecol. 1990 Jun;162(6):1406-9; discussion 1409-11 [2360573.001]
  • [Cites] Oncol Rep. 2005 Nov;14 (5):1365-9 [16211310.001]
  • [Cites] Gynecol Oncol. 2006 Jun;101(3):429-35 [16337995.001]
  • [Cites] Gynecol Oncol. 2001 Jun;81(3):404-7 [11371129.001]
  • [Cites] Br J Cancer. 2004 Sep 13;91(6):1019-24 [15305186.001]
  • [Cites] Gynecol Oncol. 2007 Jan;104(1):95-9 [16996117.001]
  • [Cites] Cancer Res. 1986 Apr;46(4 Pt 2):1972-9 [3512077.001]
  • [Cites] Cancer Res. 1996 Apr 15;56(8):1842-50 [8620502.001]
  • [Cites] Strahlenther Onkol. 1999 Feb;175(2):78-83 [10065143.001]
  • [Cites] Radiat Res. 1995 Sep;143(3):309-15 [7652169.001]
  • (PMID = 20205484.001).
  • [ISSN] 1179-1950
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 170
  •  go-up   go-down


12. Nishio S, Katsumata N, Matsumoto K, Tanabe H, Yonemori K, Kohno T, Shimizu C, Ando M, Kasamatsu T, Fujiwara Y: Analysis of the clinicopathological prognosis of stage IVb cervical carcinoma. Oncol Rep; 2008 Feb;19(2):497-503
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the clinicopathological prognosis of stage IVb cervical carcinoma.
  • The aim of this study was to evaluate the clinicopathological prognostic factors in patients with stage IVb cervical carcinoma (CC).
  • All patients with stage IVb CC included in the study were diagnosed from 1997 to 2006 at the National Cancer Center Hospital.
  • We retrospectively examined clinicopathological parameters in these patients, including the efficacy of chemotherapy.
  • Thirty-six patients (median age 54 years) were diagnosed with stage IVb CC.
  • As initial treatment, 4 patients underwent hysterectomy, 13 received chemotherapy, 17 received radiotherapy, and the remaining 2 patients refused treatment.
  • A total of 21 patients received chemotherapy, of which 13 were initial cases, 7 were persistent/recurrence cases, and 1 was a postoperative adjuvant case; 15 patients were never treated with chemotherapy.
  • On univariate analysis, poor performance status (PS) and non-chemotherapy groups were considered poor prognostic factors, respectively.
  • On multivariate analysis, poor PS (p=0.007; hazard ratio, 2.64) and non-chemotherapy (p=0.016; hazard ratio, 6.03) were independent prognostic factors of survival, respectively.
  • Poor PS and non-chemotherapy groups were found to have poor prognosis in patients with stage IVb CC.
  • Chemotherapy may improve the survival for stage IVb CC.
  • [MeSH-major] Carcinoma / drug therapy. Carcinoma / pathology. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome


13. Nagao S, Fujiwara K, Oda T, Ishikawa H, Koike H, Tanaka H, Kohno I: Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study. Gynecol Oncol; 2005 Mar;96(3):805-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study.
  • OBJECTIVES: This is a pilot study for a future trial to assess the efficacy and safety of combination chemotherapy with docetaxel and carboplatin in advanced or recurrent uterine cervix cancer.
  • METHODS: The patients eligible for this study had histologically confirmed, advanced (stage IB2-IV) or recurrent uterine cervix cancer.
  • Chemotherapy was repeated in 1-6 courses depending on the purpose of the therapy.
  • The distribution of stage was IB2, 3; IIB, 8; IIIB, 3; IVB, 1; recurrent, 2.
  • There were 9 squamous cell carcinomas, 6 adenocarcinomas, 1 adenosquamous cell carcinoma, and 1 small cell carcinoma.
  • All 5 adenocarcinoma patients in the neoadjuvant chemotherapy group responded including 1 pathological CR.
  • CONCLUSIONS: The combination of docetaxel and carboplatin is an effective and safe treatment for uterine cervix cancer.
  • Further evaluation particularly targeted on cervical adenocarcinoma is warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Carboplatin / adverse effects. Female. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Pilot Projects. Taxoids / administration & dosage. Taxoids / adverse effects

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721429.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin
  •  go-up   go-down


14. Kim YS, Kim JH, Ahn SD, Lee SW, Shin SS, Nam JH, Kim YT, Kim YM, Kim JH, Choi EK: High-dose extended-field irradiation and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys; 2009 Aug 1;74(5):1522-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose extended-field irradiation and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic lymph nodes.
  • PURPOSE: To determine the efficacy and toxicity of extended-field radiotherapy (RT) with concurrent platinum-based chemotherapy in patients with uterine cervical carcinoma and positive para-aortic nodes.
  • METHODS AND MATERIALS: We retrospectively reviewed the results for 33 women with Stage IB-IVB cervical cancer.
  • Each patient had received 59.4 Gy, including a three-dimensional conformal boost to the para-aortic lymph nodes and 41.4-50.4 Gy of external beam radiotherapy to the pelvis.
  • Each patient also underwent six or seven applications of high-dose-rate brachytherapy (median, 5 Gy to point A at each session).
  • Of the 33 women, 15 had no evidence of disease, 6 had persistent disease, 4 developed in-field failures, and 6 developed distant failures.
  • CONCLUSION: Concurrent chemoradiotherapy with extended-field radiotherapy is feasible in women with uterine cervical carcinoma and positive para-aortic lymph nodes, with acceptable late morbidity and a high survival rate, although it was accompanied by substantial acute toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / radiotherapy. Adult. Aged. Aorta. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / administration & dosage. Combined Modality Therapy / methods. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Iridium Radioisotopes / therapeutic use. Lymphatic Metastasis / radiotherapy. Middle Aged. Paclitaxel / administration & dosage. Radiotherapy / adverse effects. Radiotherapy / methods. Radiotherapy Dosage. Remission Induction. Retrospective Studies. Treatment Outcome


15. Chitapanarux I, Tonusin A, Sukthomya V, Charuchinda C, Pukanhapan N, Lorvidhaya V: Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer. Gynecol Oncol; 2003 Jun;89(3):402-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer.
  • OBJECTIVE: The goal of this study was to evaluate the efficacy and tolerability of irinotecan plus cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer.
  • METHODS: Chemotherapy-naive patients with metastatic or recurrent disease and at least one measurable tumor site received irinotecan (60 mg/m(2) IV infusion over 90 min) on Days 1, 8, and 15, followed by cisplatin (60 mg/m(2) IV over 90 min) on Day 1, every 28 days for a maximum of six cycles.
  • Seven patients were stage IVB at diagnosis.
  • Median time to relapse was 13.4 months, with a median survival time of 16.9 months.
  • Nine patients (30%) developed grade 3 neutropenia, and only grade 1-2 acute and late diarrhea were observed in 20 and 40%, respectively.
  • A patient developed pancolitis after the sixth cycle.
  • There were no chemotherapy-related deaths.
  • CONCLUSION: The combination of irinotecan and cisplatin is a clinically active regimen for metastatic and/or recurrent cervical cancer with acceptable tolerability.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Carcinoma, Squamous Cell / drug therapy. Neoplasm Recurrence, Local / drug therapy. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Middle Aged. Neoplasm Metastasis. Prospective Studies. Survival Rate


16. Nagao S, Fujiwara K, Oda T, Ishikawa H, Koike H, Tanaka H, Kohno I: Docetaxel and carboplatin combination chemotherapy in advanced or recurrent cervix cancer of the uterus. A pilot study. J Clin Oncol; 2004 Jul 15;22(14_suppl):5099

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel and carboplatin combination chemotherapy in advanced or recurrent cervix cancer of the uterus. A pilot study.
  • : 5099 Background: This is a pilot study to assess an efficacy and safety of combination chemotherapy of docetaxel and carboplatin in advanced or recurrent uterine cervix cancer for the future trial.
  • METHODS: The patients eligible for this study were those who were histologically confirmed (squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma), advanced (stage IB2-IV) or recurrent uterine cervix cancer.The patient must have measurable lesion and must have sufficient bone marrow, renal, and liver function.
  • Chemotherapy was repeated 1-6 courses depending on the purpose of the therapy.
  • However, confirmation of the objective response no less than 4 weeks after criteria for response are first met was not required in patients who underwent chemotherapy as a neoadjuvant setting.
  • Distribution of stage was IB2; 1, IIB; 6, IIIB; 2, IVB; 2, Recurrent; 2.
  • There were 6 squamous cell carcinomas, 5 adenocarcinomas and 1 adenosquamous cell carcinoma.
  • All 5 adenocarcinoma patients under neoadjuvant chemotherapy setting responded including 1 pathological CR.
  • CONCLUSIONS: Combination of docetaxel and carboplatin is effective and safe treatment for uterine cervix cancer.
  • Further evaluation particularly targeted on cervical adenocarcinoma is warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015322.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Majem M, Martinez M, Galiana R, Montes A, Cardenal F, Rodon J, Nogues J, Perez FJ, Gomez J, Mesia R: Analysis of 46 patients with nasopharyngeal carcinoma treated with hyperfractionated radiotherapy in a single institution. J Clin Oncol; 2004 Jul 15;22(14_suppl):5616

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of 46 patients with nasopharyngeal carcinoma treated with hyperfractionated radiotherapy in a single institution.
  • : 5616 Background: New fractionations in radiotherapy (RT) on head and neck cancer have emerged to increase local control.
  • Addition of chemotherapy (CT) in advanced nasopharyngeal tumors tries to decrease local and distant recurrence.
  • We report our results in non-Asiatic patients (pts) with advanced nasophayngeal carcinoma treated with induction CT and hyperfractionated RT (hfRT).
  • METHODS: Forty-six pts with nasopharyngeal carcinoma have been treated from 10/94 to 05/02: 79% male and 21% female, median age: 51 years (18-76).
  • Hystologic subtypes: 33% keratonizing squamous cell carcinoma (KSCC), 8% nonKSCC, 59% undifferentiated carcinoma.
  • Stage (2002 UICC Classification): 4 IIa, 11 IIb, 14 III, 10 IVa and 7 IVb.
  • The median HfRT dose was 80.4 Gy administered at 1.2 Gy/ fraction twice day.
  • Late side effects related to HfRT were mainly cervical fibrosis, xerostomy and trismus.
  • Two of these pts (1 local, 1 nodal) are free of disease with salvage therapy.
  • CONCLUSIONS: hfRT might be an effective treatment for nasopharyngeal carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015277.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Monk B, Mas L, Zarba JJ, Oaknin A, Tarpin C, Termrungruanglert W, Alber JA, Ding J, Stutts NW, Pandite LN: A randomized phase II study: Pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L+P) in advanced and recurrent cervical cancer (CC). J Clin Oncol; 2009 May 20;27(15_suppl):5520

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II study: Pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L+P) in advanced and recurrent cervical cancer (CC).
  • METHODS: Patients (pts) with measurable stage IVB, persistent or recurrent squamous or adenocarcinoma of the cervix not amenable to curative therapy; 0-1 prior regimens in the metastatic setting; ECOG PS 0-1; were randomized 1:1:1 to each of 3 treatment groups; not prescreened for EGFR or HER2 status.
  • Treatment consisted of P 800mg QD; L 1,500 mg QD; L+P: P 400 mg + L 1,000 mg QD; the doses were escalated to P 800 mg + L 1,500 mg after 20 pts treated at 400 mg + 1,000 mg.
  • Therapy continued until progression (PD), withdrawal due to adverse events (AEs), or withdrawal of consent.
  • A hierarchical testing procedure was applied comparing L+P vs L followed by L+P vs P and P vs L.
  • Stage IVB: 5%; recurrent 62%; persistent 34%.
  • 86% had prior radiotherapy (45% with chemotherapy); 42% had prior chemotherapy for recurrent/persistent disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962484.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Ikeda O, Mizukami N, Murata Y, Arakawa A, Katabuchi H, Okamoto H, Yasunaga T, Tsunawaki A, Yamashita Y: Randomized comparison of intra-arterial chemotherapy versus intra-arterial chemotherapy and gelfoam embolization for treatment of advanced cervical carcinoma. Cardiovasc Intervent Radiol; 2005 Nov-Dec;28(6):736-43
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized comparison of intra-arterial chemotherapy versus intra-arterial chemotherapy and gelfoam embolization for treatment of advanced cervical carcinoma.
  • PURPOSE: We evaluated the effects of intra-arterial infusion therapy by comparing the results obtained with a combination of intra-arterial anticancer drugs with and without transcatheter arterial embolization (TAE) in patients with cervical cancer.
  • METHODS: Between April 1999 and March 2003, intra-arterial therapy was administered to 45 patients (mean age 49 years) with cervical cancer.
  • Of these, 18 had stage IIb , 4 had stage IIIa, 19 had stage IIIb, and 4 had stage IVb cancer; the histopathologic types were squamous cell carcinoma (n = 35), adenocarcinoma (n = 8), and adenosquamous carcinoma (n = 2).
  • A total of 45 patients gave their informed consent and were randomized on a continuous basis into one of three groups according to the therapeutic protocols: group A consisted of 15 patients who received cisplatin, group B consisted of 17 patients who received cisplatin, mitomycin, doxorubicin hydrochloride, and 5-fluorouracil, and group C consisted of 13 patients who received cisplatin and TAE.
  • Each protocol was administered twice with a 3 week interval between treatments.
  • The efficacy of treatment was evaluated on the basis of the tumor reduction ratio (%) using MR imaging and the side effects were analyzed.
  • Although all group C patients developed severe pain after TAE, the pain was controlled with analgesics.
  • [MeSH-major] Carcinoma / therapy. Drug Therapy, Combination. Embolization, Therapeutic / methods. Gelatin Sponge, Absorbable / therapeutic use. Hemostatics / therapeutic use. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / adverse effects. Antibiotics, Antineoplastic / therapeutic use. Antimetabolites, Antineoplastic / adverse effects. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Cervix Uteri / pathology. Cisplatin / adverse effects. Cisplatin / therapeutic use. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Female. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Humans. Infusions, Intra-Arterial / methods. Magnetic Resonance Imaging / methods. Middle Aged. Mitomycin / adverse effects. Mitomycin / therapeutic use. Treatment Outcome


20. Loizzi V, Cormio G, Cuccovillo A, Fattizzi N, Selvaggi L: Two cases of endometrial cancer diagnosis associated with bone metastasis. Gynecol Obstet Invest; 2006;61(1):49-52
Hazardous Substances Data Bank. PLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of endometrial cancer diagnosis associated with bone metastasis.
  • BACKGROUND: Endometrial adenocarcinoma is commonly seen in postmenopausal women and uterine bleeding is the first sign in 90% of the cases.
  • We report two endometrial cancer patients with metastasis to the tibia and cervical vertebra at the time of primary disease.
  • CASES: Two patients were diagnosed with stage IVB endometrial cancer with involvement of the tibia and cervical column, respectively.
  • The first case was treated with 8 cycles of platinum, doxorubicin, and cyclophosphamide, but she died 3 months after the completion of chemotherapy as a result of progressive disease.
  • The second case received surgery followed by chemotherapy with cisplatin and doxorubicin, but she died 2 months later.
  • CONCLUSIONS: These cases highlight the rare and unusual presentation of endometrial cancer.
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Density Conservation Agents / administration & dosage. Cervical Vertebrae. Cyclophosphamide / administration & dosage. Diphosphonates / administration & dosage. Doxorubicin / administration & dosage. Fatal Outcome. Female. Humans. Imidazoles / administration & dosage. Middle Aged. Platinum / administration & dosage. Spinal Neoplasms / diagnosis. Spinal Neoplasms / drug therapy. Spinal Neoplasms / secondary. Tibia

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16192733.001).
  • [ISSN] 0378-7346
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 49DFR088MY / Platinum; 6XC1PAD3KF / zoledronic acid; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  • [Number-of-references] 22
  •  go-up   go-down


21. Yao K, Takahashi H, Inagi K, Nakayama M, Makoshi T, Nagai H, Okamoto M: Carcinoma of the nasopharynx: analysis of treatment results in 91 patients. Acta Otolaryngol Suppl; 2002;(547):20-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the nasopharynx: analysis of treatment results in 91 patients.
  • The outcome of 91 patients (69 males, 22 females; age range 16-82 years) with nasopharyngeal carcinoma treated in our hospital between 1971 and 1999 was evaluated.
  • The 1997 International Union Against Cancer classification was used for disease staging.
  • The 5-year survival rates were as follows: 66.7% (n = 3) for Stage I; 100% (n = 2) for Stage IIA; 90.9% (n = 11) for Stage IIB; 78.8% (n = 25) for Stage III; 53.0% (n = 29) for Stage IVA; 37.5% (n = 16) for Stage IVB; and 20.0% (n = 5) for Stage IVC.
  • The disease-free cumulative 3-year survival rates of the patients classified based on initial therapy were as follows: radiation alone, 50.0% (n = 28); combined radiotherapy and chemotherapy that included an undefined anti-cancer drug, 67.2% (n = 39); combined radiotherapy and chemotherapy that included carboplatin (CBDCA), 92.3% (n = 19).
  • Stage IVC patients were excluded from the analysis.
  • We conclude that combined therapy, including chemotherapy with CBDCA, is necessary for the treatment of nasopharyngeal carcinoma.
  • In terms of radiation therapy, a field covering the bilateral cervical regions seemed to produce favorable results, even if cervical node metastasis was not confirmed by palpation at the first hospital visit.
  • Key words: carboplatin, chemotherapy,
  • [MeSH-major] Carcinoma / mortality. Carcinoma / therapy. Nasopharyngeal Neoplasms / mortality. Nasopharyngeal Neoplasms / therapy. Outcome Assessment (Health Care) / statistics & numerical data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12212588.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


22. Moore KN, Herzog TJ, Lewin S, Giuntoli RL, Armstrong DK, Rocconi RP, Spannuth WA, Gold MA: A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol; 2007 May;105(2):299-303
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer.
  • OBJECTIVE: Cisplatin-based combination therapy produces higher response rates and improved survival, in comparison to single-agent cisplatin in the treatment of cervical cancer.
  • The objective of this study was to compare response rate and survival in patients with cervical cancer treated with PT or CT.
  • METHODS: A retrospective search of databases at the University of Oklahoma, Washington University-Barnes Jewish Christian Hospitals, Johns Hopkins University, and University of Alabama at Birmingham identified patients with stage IVB, recurrent or persistent cervical cancer who were treated with PT or CT.
  • There were no statistical differences between the groups in terms of demographics, prior radiation therapy, or median number of cycles.
  • Because of its ease of administration and improved toxicity profile, CT should be considered in the treatment of advanced, recurrent or progressive cervical cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Carboplatin / administration & dosage. Carboplatin / adverse effects. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Cisplatin / administration & dosage. Cisplatin / adverse effects. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Retrospective Studies


23. Saito I, Kitagawa R, Fukuda H, Shibata T, Katsumata N, Konishi I, Yoshikawa H, Kamura T: A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505). Jpn J Clin Oncol; 2010 Jan;40(1):90-3
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505).
  • A randomized controlled trial has been started in Japan to compare the utility of palliative chemotherapy containing paclitaxel and carboplatin (TC) with paclitaxel and cisplatin (TP) as a standard treatment for patients with the newly diagnosed Stage IVB, persistent or recurrent cervical cancer who are not amenable to curative treatment with local therapy.
  • This trial was designed to evaluate the non-inferiority of TC as measured by the number of hospitalized days as an indicator of quality of life (QOL) when compared with TP combination therapy.
  • Secondary endpoints are progression-free survival, response rates, adverse events, severe adverse events and the proportion of non-hospitalization periods compared with planned treatment periods.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Cisplatin / administration & dosage. Clinical Protocols. Female. Follow-Up Studies. Humans. Japan. Neoplasm Metastasis / drug therapy. Neoplasm Staging. Paclitaxel / administration & dosage. Quality of Life. Recurrence. Research Design

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19825815.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


24. Ayhan A, Taskiran C, Celik C, Yuce K, Kucukali T: The influence of cytoreductive surgery on survival and morbidity in stage IVB endometrial cancer. Int J Gynecol Cancer; 2002 Sep-Oct;12(5):448-53
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of cytoreductive surgery on survival and morbidity in stage IVB endometrial cancer.
  • The purpose of this study was to detect possible survival advantages of surgical cytoreduction and different adjuvant treatment regimens for stage IVB endometrial cancer patients, and also to evaluate the prognostic importance of surgico-pathological risk factors and surgical morbidity rates.
  • Thirty-seven FIGO stage IVB endometrial cancer patients treated at the Hacettepe University Hospital between 1977 and 1998 were included in this study.
  • Optimal cytoreduction was defined as a surgical procedure leaving the patient with < or =1 cm residual disease in maximal diameter.
  • Fourteen (38%) patients received both radiotherapy and chemotherapy, 10 (27%) patients received only radiotherapy and the other 10 (27%) patients received only chemotherapy.
  • Three patients refused any type of adjuvant therapy.
  • As an adjuvant treatment, concomitant cisplatin and radiotherapy revealed 54 months median survival compared to 15 and 13 months in patients treated with only radiotherapy and only chemotherapy, respectively.
  • By univariate analysis, extra-abdominal metastases, suboptimal cytoreduction, visible tumoral mass after cytoreduction, pelvic-para-aortic lymphatic metastases, and cervical invasion were found to be significant predictors of poor survival.
  • In multivariate analysis, optimal cytoreduction, concomitant cisplatin-radiotherapy treatment, and extra-abdominal metastases were significant.
  • We conclude that optimal cytoreduction achieved significant survival benefit for stage IVB endometrial cancer patients with a reasonable surgical morbidity rate.
  • As an adjuvant treatment, concomitant cisplatin and radiotherapy was the best choice.
  • [MeSH-major] Carcinoma / pathology. Carcinoma / surgery. Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Chemotherapy, Adjuvant. Chi-Square Distribution. Combined Modality Therapy. Female. Humans. Hysterectomy / methods. Middle Aged. Neoplasm Staging. Probability. Prognosis. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Risk Assessment. Sensitivity and Specificity. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12366661.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Venkitaraman R, Ramanan SG, Sagar TG: Nasopharyngeal cancer of childhood and adolescence: a single institution experience. Pediatr Hematol Oncol; 2007 Oct-Nov;24(7):493-502
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasopharyngeal cancer of childhood and adolescence: a single institution experience.
  • Nasopharyngeal cancer is rare in childhood and results with radiotherapy are far from encouraging.
  • A total of 52 patients with stage I to IVB nasopharygeal cancer and age <18, received radiotherapy to 60-66 Gy in 2-Gy fractions to the nasopharynx and cervical nodes, while 22 of these patients also received chemotherapy with cisplatin and 5 FU.
  • Three-year disease-free survival with concurrent chemotherapy was 82% compared to 40% for patients who had radiotherapy alone (p = .001; HR 0.33; 95% CI 0.25-0.74).
  • The 3-year overall survival in the patients who received radiotherapy was 72% and that in the patients who received concurrent chemotherapy was 77% (p = .38).
  • A statistically significant improvement in disease-free survival was observed with concurrent chemoradiation in nonmetastatic nasopharyngeal cancer in young patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Child. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Neoplasm Staging


26. Cetina L, Rivera L, Candelaria M, de la Garza J, Dueñas-González A: Chemoradiation with gemcitabine for cervical cancer in patients with renal failure. Anticancer Drugs; 2004 Sep;15(8):761-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiation with gemcitabine for cervical cancer in patients with renal failure.
  • The prognosis of cervical cancer patients with renal failure secondary to obstructive uropathy is poor.
  • Our objective was to analyze our experience in the management with chemoradiation of untreated cervical cancer patients complicated by obstructive nephropathy and kidney dysfunction.
  • Untreated patients with cervical cancer and renal failure as manifested by raised serum creatinine were treated with pelvic radiotherapy concurrently with weekly gemcitabine at 300 mg/m2.
  • Response, toxicity and renal function pre- and post-therapy were evaluated.
  • Eight FIGO stage IIIB and one IVB patients were treated.
  • Pre-treatment serum creatinine ranged from 1.6 to 18.5 mg/100 ml (median 3.3, mean 6.8) and creatinine clearance varied from 4 to 57 mg/ml/min (median 17, mean 22.1).
  • All patients had improvement in creatinine clearance (pre-therapy 22.78, post-therapy 54.3 mg/ml/min) (p=0.0058) and all but one normalized serum creatinine.
  • In this setting where cisplatin-based therapy is contraindicated, the use of gemcitabine may be considered.
  • [MeSH-major] Chemotherapy, Adjuvant / methods. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Radiotherapy, Adjuvant / methods. Renal Insufficiency / drug therapy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Brachytherapy / methods. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Creatinine / blood. Drug Administration Schedule. Drug Evaluation / methods. Female. Follow-Up Studies. Humans. Injections, Intravenous. Kidney Function Tests / methods. Mexico. Middle Aged. Neoplasm Staging. Radiation-Sensitizing Agents / administration & dosage. Radiation-Sensitizing Agents / adverse effects. Radiation-Sensitizing Agents / therapeutic use. Time Factors. Treatment Outcome. Urethral Obstruction / complications

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15494637.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; 0W860991D6 / Deoxycytidine; AYI8EX34EU / Creatinine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


27. Dowdy SC, Boardman CH, Wilson TO, Podratz KC, Hartmann LC, Long HJ: Multimodal therapy including neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for stage IIB to IV cervical cancer. Am J Obstet Gynecol; 2002 Jun;186(6):1167-73
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodal therapy including neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for stage IIB to IV cervical cancer.
  • OBJECTIVE: The purpose of this study was to determine the survival rates and toxicity levels that are associated with multimodal therapy (including neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin [MVAC]) in patients with stage IIB to IVB cervical cancer.
  • STUDY DESIGN: We retrospectively reviewed the cases of 49 patients who were treated between 1989 and 1997 with neoadjuvant MVAC for advanced cervical cancer.
  • Combined therapy after MVAC included operation in 34 patients (69%) and radiation in 41 patients (84%).
  • Five-year disease-specific survival for patients with stage III disease was 60%.
  • CONCLUSION: For patients with advanced cervical cancer, neoadjuvant MVAC had a high response rate (90%) and an acceptable toxicity level.
  • Compared with historic control subjects, multimodal treatment may be associated with improved rates of pelvic control.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Doxorubicin / therapeutic use. Methotrexate / therapeutic use. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / pathology. Vinblastine / therapeutic use
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Neoplasm, Residual / pathology. Neutropenia / chemically induced. Retrospective Studies. Survival Analysis. Treatment Outcome


28. Cohen JG, Kapp DS, Shin JY, Urban R, Sherman AE, Chen LM, Osann K, Chan JK: Small cell carcinoma of the cervix: treatment and survival outcomes of 188 patients. Am J Obstet Gynecol; 2010 Oct;203(4):347.e1-6
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of the cervix: treatment and survival outcomes of 188 patients.
  • OBJECTIVE: To determine the clinicopathologic factors associated with survival in neuroendocrine small cell cervical cancer patients.
  • RESULTS: Of 188 patients, 135 had stages I-IIA, 45 stages IIB-IVA, and 8 stage IVB disease.
  • A total of 55.3% underwent surgery, 16.0% had chemoradiation, 12.8% radiation, and 3.2% chemotherapy alone.
  • The 5-year disease-specific survival in stage I-IIA, IIB-IVA, and IVB disease was 36.8%, 9.8%, and 0%, respectively (P < .001).
  • Adjuvant chemotherapy or chemoradiation was associated with improved survival in patients with stages IIB-IVA disease compared with those who did not receive chemotherapy (17.8% vs 6.0%; P = .04).
  • On multivariable analysis, early-stage disease and use of chemotherapy or chemoradiation were independent prognostic factors for improved survival.
  • CONCLUSION: Use of adjuvant chemotherapy or chemoradiation was associated with higher survival in small cell cervical cancer patients.
  • [MeSH-major] Carcinoma, Small Cell / mortality. Carcinoma, Small Cell / therapy. Uterine Cervical Neoplasms / mortality. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Etoposide / therapeutic use. Female. Humans. Hysterectomy. Kaplan-Meier Estimate. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Registries

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20579961.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


29. Chura JC, Shukla K, Argenta PA: Brain metastasis from cervical carcinoma. Int J Gynecol Cancer; 2007 Jan-Feb;17(1):141-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastasis from cervical carcinoma.
  • The aim of this study was to describe the features of patients with brain metastasis from cervical cancer.
  • Twelve patients with brain metastasis from cervical cancer were identified.
  • Information regarding symptoms, treatment, and survival was analyzed.
  • Median patient age at initial diagnosis of cervical cancer was 43.5 years (range 29-57 years) compared with 44.5 years (range 31-58 years) at identification of brain metastasis.
  • Six patients had FIGO stage IB disease; three had stage IIB disease; and one each had stage IIIA, IIIB, and IVB disease.
  • The median interval from diagnosis of cervical cancer to identification of brain metastasis was 17.5 months (range 1.1-96.1 months).
  • Five patients who received chemotherapy after brain irradiation had a median survival of 4.4 months compared to 0.9 months for those who received no additional treatment after brain irradiation (P= .016).
  • Most patients with brain metastasis from cervical cancer presented with neurologic sequelae.
  • Survival after diagnosis of brain metastasis was poor; however, patients who received chemotherapy after brain irradiation appeared to have improved survival.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / therapy. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17291245.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Kantardzic N: Concurrent chemoradiation for cervical cancer: results of five randomized trials. Med Arh; 2010;64(6):368-70
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiation for cervical cancer: results of five randomized trials.
  • BACKGROUND: Cervical cancer is the second most common cancer among women's in Bosnia and Herzegovina.
  • Most of these women's in the time of diagnosis are with advanced disease.
  • In the 1999 NCI issued a clinical alert, recommending that chemo radiation should be implemented as new treatment for these patients.
  • AIM: To determine a survival, loco regional control and toxicity in patients with cervical carcinoma treated in Institute o Oncology from 2000-2006.
  • Data of five hundred and fourteen patients diagnosed as cervical cancer FIGO stage Ib, -IVb and presented in our Institute, were analyzed.
  • We treated 345 with combined chemo radiotherapy, 162 with radiotherapy alone and 7 patients with symptomatic therapy.
  • Subgroup of 148 patients with advanced disease and grade of tumor unknown and 136 patients with known grade of tumor were compared for time to local progression, time to distant metastasis and time to death.
  • Of 514 patients 492 were treated with curative intentions and 15 got palliative treatment.
  • All treated patients finished their planed therapy.
  • Patients with advanced disease and unknown grade of tumor cells had significantly shorter time to local progression, distant metastasis and death.
  • CONCLUSION: The combined therapy for cervical cancer is the safe and good tolerated treatment.
  • There were no deaths caused by treatment.
  • [MeSH-major] Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Middle Aged. Survival Rate

  • Genetic Alliance. consumer health - Cervical cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21218758.001).
  • [Journal-full-title] Medicinski arhiv
  • [ISO-abbreviation] Med Arh
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


31. Suprasert P, Charoenkwan K, Cheewakriangkrai C: Outcomes of advanced and recurrent cervical cancer treated with cisplatin and generic topotecan: retrospective analysis in a tertiary care hospital in Thailand. J Gynecol Oncol; 2010 Dec 30;21(4):237-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of advanced and recurrent cervical cancer treated with cisplatin and generic topotecan: retrospective analysis in a tertiary care hospital in Thailand.
  • OBJECTIVE: Retrospective evaluation of the outcome of stage IVB, recurrent or persistent cervical cancer treated with cisplatin and generic topotecan (CT) in a tertiary care hospital in Thailand.
  • The treatment protocol consisted of IV topotecan 0.75 mg/m(2) on days 1, 2, and 3; combined with cisplatin 50 mg/m(2) IV on day 1 and repeated every 21 days until progression or unacceptable toxicity for a maximum of 6 cycles.
  • The adverse effects of the treatments were also determined.
  • RESULTS: Twenty-one cervical cancer patients received the CT regimen.
  • With 87 cycles of chemotherapy, the most common grade 3 & 4 hematologic toxicity was neutropenia (57.9%).
  • CONCLUSION: Advanced and recurrent cervical cancer patients treated with cisplatin and generic topotecan had a favorable outcome with manageable toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4626-33 [15911865.001]
  • [Cites] Anticancer Drugs. 2005 Oct;16(9):901-9 [16162966.001]
  • [Cites] Expert Opin Pharmacother. 2007 Feb;8(2):227-36 [17257092.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Gynecol Oncol. 2009 Nov;115(2):285-9 [19726073.001]
  • [Cites] J Clin Oncol. 1985 Aug;3(8):1079-85 [3894589.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4649-55 [19720909.001]
  • (PMID = 21278885.001).
  • [ISSN] 2005-0399
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3026302
  • [Keywords] NOTNLM ; Advance / Cervical cancer / Cisplatin / Recurrence / Topotecan
  •  go-up   go-down


32. Downs LS Jr, Judson PL, Argenta PA, Carson LF, Boente MP: A phase I study of ifosfamide, paclitaxel, and carboplatin in advanced and recurrent cervical cancer. Gynecol Oncol; 2004 Nov;95(2):347-51
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of ifosfamide, paclitaxel, and carboplatin in advanced and recurrent cervical cancer.
  • OBJECTIVES: To determine toxicity and establish a maximum tolerated dose of outpatient therapy with ifosfamide, paclitaxel, and carboplatin in women with advanced and recurrent cervical cancer.
  • METHODS: Eligible patients had stage IVB, recurrent or persistent cervical cancer that was not amenable to curative treatment with surgery or radiation therapy.
  • RESULTS: Twelve patients, aged 29 to 71, received 64 treatments and were evaluable for toxicity.
  • Two patients had received prior radiation therapy without chemotherapy, and seven patients had received radiation therapy with concurrent chemotherapy.
  • CONCLUSIONS: Combination therapy with ifosfamide 2 g/m(2), paclitaxel 175 mg/m(2), carboplatin AUC = 5 appears to be a safe regimen for the outpatient treatment of women with advanced or recurrent cervical cancer and warrants phase II investigation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Neoplasm Recurrence, Local / drug therapy. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Ambulatory Care. Carboplatin / administration & dosage. Carboplatin / adverse effects. Dose-Response Relationship, Drug. Female. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Middle Aged. Paclitaxel / administration & dosage. Paclitaxel / adverse effects

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15491756.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


33. Deng GH, Zhang X, Wu LY: [Clinicopathological analysis of nine cases of small cell carcinoma of the uterine cervix]. Zhonghua Zhong Liu Za Zhi; 2010 Mar;32(3):199-202
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological analysis of nine cases of small cell carcinoma of the uterine cervix].
  • OBJECTIVE: To investigate the clinicopathologic characteristics, therapy and prognostic factors of small cell carcinoma of the uterine cervix (SCCC).
  • METHODS: Nine patients with SCCC underwent radical hysterectomy at the Cancer Hospital of CAMS between 2000 to 2009.
  • According to FIGO staging criteria, six patients were stage Ib1 disease, 2 stage Ib2 and 1 stage IVb.
  • All patients received postoperative chemotherapy, with or without radiotherapy.
  • It is necessary to use multimodality treatment for SCCC, especially the chemotherapy.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Hysterectomy. Nuclear Proteins / metabolism. Transcription Factors / metabolism. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, CD56 / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromogranin A / metabolism. Cisplatin / therapeutic use. Combined Modality Therapy. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Female. Follow-Up Studies. Humans. Lymph Node Excision. Middle Aged. Neoplasm Staging. Phosphopyruvate Hydratase / metabolism. Radiotherapy, High-Energy. Survival Rate. Synaptophysin / metabolism. Taxoids / therapeutic use

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450588.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Chromogranin A; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Nuclear Proteins; 0 / Synaptophysin; 0 / Taxoids; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; EC 4.2.1.11 / Phosphopyruvate Hydratase; Q20Q21Q62J / Cisplatin; TP protocol
  •  go-up   go-down


34. Niwa K, Kometani K, Sekiya T, Nakazawa K, Kanakura Y: Complete remission of uterine endometrial cancer with multiple lung metastases treated by paclitaxel and carboplatin. Int J Clin Oncol; 2002 Jun;7(3):197-200
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of uterine endometrial cancer with multiple lung metastases treated by paclitaxel and carboplatin.
  • Endometrial cancer is believed to have a better prognosis than cervical cancer.
  • However, this is not necessarily true for cases beyond International Federation of Gynecology and Obstetrics (FIGO) stage III, and advanced endometrial cancer with distant metastases in particular has a poor prognosis.
  • Moreover, there is no established therapy for advanced endometrial cancer.
  • Recently, we treated two patients with endometrial cancer with multiple lung metastases (FIGO stage IVb).
  • In their postoperative course, the two patients successfully underwent T-J chemotherapy [paclitaxel: 210 m/m2 over 3h; carboplatin: area under the curve (AUC) 5].
  • Multiple lung shadows in chest X-P and computed tomography (CT) were reduced in number and size after two courses of T-J chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Endometrioid / drug therapy. Endometrial Neoplasms / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Anemia. Area Under Curve. Carboplatin / administration & dosage. Disease-Free Survival. Female. Humans. Japan. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Radiography, Thoracic. Remission Induction. Time Factors. Tomography, X-Ray Computed. Uterine Hemorrhage

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12109523.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


35. Kunos CA, Waggoner S, von Gruenigen V, Eldermire E, Pink J, Dowlati A, Kinsella TJ: Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer. Clin Cancer Res; 2010 Feb 15;16(4):1298-306
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer.
  • PURPOSE: This study assessed the safety/tolerability, pharmacokinetics, and clinical activity of three times weekly i.v.
  • EXPERIMENTAL DESIGN: Patients with stage IB2 to IVB cervical cancer (n = 10) or recurrent uterine sarcoma (n = 1) were assigned to dose-finding cohorts of 2-hour 3-AP infusions during 5 weeks of cisplatin chemoradiation.
  • RESULTS: The maximum tolerated 3-AP dose was 25 mg/m(2) given three times weekly during cisplatin and pelvic radiation.
  • Ten (100%) patients with stage IB2 to IVB cervical cancer achieved complete clinical response and remained without disease relapse with a median 18 months of follow-up (6-32 months).
  • CONCLUSIONS: 3-AP was well tolerated at a three times weekly i.v.
  • Clin Cancer Res; 16(4); 1298-306.

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 2002 Sep;50(3):223-9 [12203104.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):637-42 [11849784.001]
  • [Cites] Cancer J. 2003 Jul-Aug;9(4):277-85 [12967138.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4092-100 [14519631.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):1-6 [14729598.001]
  • [Cites] Rapid Commun Mass Spectrom. 2004;18(3):285-92 [14755613.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1553-63 [15117978.001]
  • [Cites] Biochim Biophys Acta. 2004 Jun 1;1699(1-2):1-34 [15158709.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Oct;54(4):331-42 [15148626.001]
  • [Cites] J Biol Chem. 1970 Oct 25;245(20):5228-33 [4319235.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1979 Mar;5(3):317-22 [110744.001]
  • [Cites] Clin Chem. 1980 Aug;26(9):1304-8 [6772341.001]
  • [Cites] Life Sci. 1981 Mar 2;28(9):1007-14 [7012518.001]
  • [Cites] Ann Clin Lab Sci. 1989 Sep-Oct;19(5):383-8 [2802517.001]
  • [Cites] Am J Hematol. 1993 Jan;42(1):7-12 [8416301.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1523-8 [8336190.001]
  • [Cites] Cancer Res. 1995 Mar 15;55(6):1328-33 [7882331.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2245-52 [9605773.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1137-43 [10202164.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1144-53 [10202165.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1339-48 [10334517.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2912-8 [16675588.001]
  • [Cites] Clin Cancer Res. 2006 Nov 1;12(21):6337-44 [17085643.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):16-21 [17210678.001]
  • [Cites] Radiat Res. 2009 Dec;172(6):666-76 [19929413.001]
  • [Cites] Biochem Pharmacol. 2000 Apr 15;59(8):983-91 [10692563.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):2971-6 [11595684.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):40647-51 [11517226.001]
  • [Cites] Prog Biophys Mol Biol. 2001 Nov;77(3):177-268 [11796141.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):402-14 [12538494.001]
  • (PMID = 20145183.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / L30 CA130084; United States / NCI NIH HHS / CA / U01 CA062502; United States / NCI NIH HHS / CA / UO1 CA62502; United States / NCI NIH HHS / CA / K12 CA076917; United States / NCI NIH HHS / CA / CA130084-01; United States / NCI NIH HHS / CA / L30 CA130084-02; United States / NCI NIH HHS / CA / P30 CA043703; United States / NCI NIH HHS / CA / L30 CA130084-01; United States / NCI NIH HHS / CA / K12 CA76917; United States / NCI NIH HHS / CA / P30 CA43703-17
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pyridines; 0 / Thiosemicarbazones; 143621-35-6 / 3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 9008-37-1 / Methemoglobin; EC 1.17.4.- / Ribonucleotide Reductases; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS165368; NLM/ PMC2822897
  •  go-up   go-down


36. Marnitz S, Köhler C, Roth C, Füller J, Bischoff A, Wendt T, Schneider A, Budach V: Stage-adjusted chemoradiation in cervical cancer after transperitoneal laparoscopic staging. Strahlenther Onkol; 2007 Sep;183(9):473-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage-adjusted chemoradiation in cervical cancer after transperitoneal laparoscopic staging.
  • PURPOSE: To evaluate the impact of transperitoneal laparoscopic staging on choice of subsequent therapy including oncologic outcome and toxicity of chemoradiation after surgical staging.
  • PATIENTS AND METHODS: 101 patients with cervical cancer FIGO IB1-IVB underwent chemoradiation after transperitoneal laparoscopic staging.
  • RESULTS: 101 women (FIGO IB1-IVB) were laparoscopically staged.
  • Only 17/101 patients (17%) retained their original FIGO stage after laparoscopy.
  • CONCLUSION: In patients with cervical cancer, laparoscopic staging led to an upstaging of 83% of cases with significant impact on therapeutic strategies.
  • Pretherapeutic laparoscopic staging should be the basis of the primary chemoradiation in patients with cervical cancer.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Laparoscopy. Lymphatic Metastasis / radiotherapy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Carboplatin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Lymph Node Excision. Neoplasm Invasiveness. Neoplasm Staging. Radiotherapy Dosage. Rectum / pathology. Survival Rate. Urinary Bladder / pathology


37. Muggia FM, Blessing JA, Waggoner S, Berek JS, Monk BJ, Sorosky J, Pearl ML: Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol; 2005 Jan;96(1):108-11
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study.
  • OBJECTIVE: The Gynecologic Oncology Group (GOG) has studied a number of drugs to determine their activity in patients with previously treated squamous and nonsquamous cancer arising in the uterine cervix.
  • A Phase II study with intravenous vinorelbine was initiated for this purpose in patients with Stage IVB, recurrent, or persistent nonsquamous carcinomas who had received one prior chemotherapy or were not eligible for other studies.
  • The treatment consisted of vinorelbine 30 mg/m(2) on days 1 and 8, repeated every 21 days.
  • Tumor measurements and toxicities were recorded every treatment cycle.
  • Severe events, such as fatigue, hypertension, or pulmonary changes attributed to drug administration, occurred only in one or two instances.
  • CONCLUSION: With the dose schedule and assessment criteria employed, vinorelbine had only minimal activity in nonsquamous cancer of the cervix.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Uterine Cervical Neoplasms / drug therapy. Vinblastine / analogs & derivatives. Vinblastine / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adult. Aged. Carcinoma, Adenosquamous / drug therapy. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15589588.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


38. Kitamoto Y, Akimoto T, Ishikawa H, Nonaka T, Katoh H, Nakano T, Ninomiya H, Chikamatsu K, Furuya N: Acute toxicity and preliminary clinical outcomes of concurrent radiation therapy and weekly docetaxel and daily cisplatin for head and neck cancer. Jpn J Clin Oncol; 2005 Nov;35(11):639-44
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute toxicity and preliminary clinical outcomes of concurrent radiation therapy and weekly docetaxel and daily cisplatin for head and neck cancer.
  • OBJECTIVE: To examine the feasibility and efficacy of concurrent weekly docetaxel and radiation therapy as a definitive treatment for head and neck cancer (HNC).
  • METHODS: Thirty-two patients with primary HNC, who were treated with concurrent weekly docetaxel and radiation therapy, were analysed.
  • The distribution of the disease stage was as follows: Stage II, 18 patients; Stage III, 3 patients; Stage IVA, 7 patients; Stage IVB, 3 patients; the patient of cervical lymph node metastasis with unknown primary tumor was not assessable.
  • The average total dose of radiotherapy was 67.5 Gy.
  • Docetaxel (10 mg/m(2), intravenously, once a week) was given to all patients up to four cycles, and cisplatin (6 mg/m(2), intravenously, five times a week) was also administered to all patients for up to 3 weeks from the beginning of the radiation therapy.
  • At the time of the analysis, the 2 year local control and relapse-free rates in the 30 patients showing CR were 90 and 76%, respectively.
  • CONCLUSIONS: Concurrent weekly docetaxel and radiation therapy did not affect the compliance of the patients for the radiation therapy, indicating that the acute toxicities were within acceptable limits.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Radiotherapy, Conformal
  • [MeSH-minor] Acute Disease. Aged. Aged, 80 and over. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Dose Fractionation. Drug Administration Schedule. Feasibility Studies. Female. Humans. Male. Middle Aged. Mucositis / chemically induced. Taxoids / administration & dosage. Taxoids / adverse effects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16275679.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


39. Monk BJ, Mas Lopez L, Zarba JJ, Oaknin A, Tarpin C, Termrungruanglert W, Alber JA, Ding J, Stutts MW, Pandite LN: Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol; 2010 Aug 1;28(22):3562-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
  • In cervical cancer, EGFR and HER2/neu overexpression and high microvascular density correlate with survival.
  • PATIENTS AND METHODS: Patients with measurable stage IVB persistent/recurrent cervical carcinoma not amenable to curative therapy and at least one prior regimen in the metastatic setting were randomly assigned in a ratio of 1:1:1 to pazopanib at 800 mg once daily, lapatinib at 1,500 mg once daily, or lapatinib plus pazopanib combination therapy (lapatinib at 1,000 mg plus pazopanib at 400 mg once daily or lapatinib at 1,500 mg plus pazopanib at 800 mg once daily).
  • Therapy continued until progression or withdrawal because of adverse events (AEs).
  • The futility boundary was crossed at the planned interim analysis for combination therapy compared with lapatinib therapy, and the combination was discontinued.
  • Most patients (62%) had recurrent cancer.
  • CONCLUSION: This study confirms the activity of antiangiogenesis agents in advanced and recurrent cervical cancer and demonstrates the benefit of pazopanib based on the prolonged PFS and favorable toxicity profile.
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pyrimidines / administration & dosage. Quinazolines / administration & dosage. Sulfonamides / administration & dosage. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Drug Delivery Systems. Female. Humans. Middle Aged. Protein Kinase Inhibitors / therapeutic use. Recurrence. Retreatment






Advertisement